Status:
COMPLETED
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder
Lead Sponsor:
LanZhou University
Conditions:
Bladder Neoplasms
Eligibility:
All Genders
26-72 years
Phase:
PHASE2
Brief Summary
Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown virtue than that use chemical or biological drugs alone in the treatment of some malignant tumor. Here we invest...
Detailed Description
Methods From July 1996 to November 2003, a total of 138 cases of bladder cancer underwent TURBT or partial cystectomy were entered the trail. They were divided into 3 groups randomly: 1, EPI plus BCG;...
Eligibility Criteria
Inclusion
- primary single or multiple (more than 2 tumors) pTa to pT1 transitional cell carcinoma, solitary or multiple grade Ⅲ tumors and primary or concomitant carcinoma in situ of the bladder were included in the study
Exclusion
- Previous radiotherapy, intravesicial or systemic chemotherapy within 3 months of the study, presence of a second primary malignancy and transitional cell carcinoma of the upper urinary tract or prostatic urethra, invasion of periurethral prostatic ducts, prostatic gland or stroma were exclusion criteria
Key Trial Info
Start Date :
June 1 1996
Trial Type :
INTERVENTIONAL
End Date :
July 1 2003
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT00343356
Start Date
June 1 1996
End Date
July 1 2003
Last Update
June 22 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.